We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.
12 Dec 2022
We respond to research about a potential new treatment for advanced breast cancer patients
Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said:
08 Dec 2022
We respond to research about radiotherapy and long-term breast cancer survival
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has responded to research presented at the 13th European Breast Cancer Conference about radiotherapy and long-term survival.
18 Nov 2022
We respond to research about the benefits of exercise
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research published in JAMA Open Network about the benefits of exercise for women recovering from breast cancer.
18 Nov 2022
We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research presented at the 13th European Breast Cancer Conference. This research showed that women who have benign breast conditions, including cysts and fibroadenomas, have a higher risk of developing breast cancer in the long term.
17 Nov 2022
We respond to latest NHSE Cancer Wait Times data
Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, has commented on the latest NHS England Cancer Wait Times data.
11 Nov 2022
We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS was "devastating".
10 Nov 2022
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the Faster Diagnosis Standard to be raised to 95%.
13 Oct 2022
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo for use on the NHS in Scotland was fantastic news.
10 Oct 2022
Pembrolizumab in combination with chemo is approved for use on the NHS in Scotland
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
10 Oct 2022
We welcome approval of palbociclib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS was absolutely fantastic news for breast cancer patients.
23 Sept 2022
We respond to research about breast cancer surgery margins
22 Sept 2022